Multiple Myeloma Clinical Trials in Chicago, Illinois

15 studies are recruiting for multiple myeloma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Cancer Treatment Centers of America-Chicago, Chicago, Illinois

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

4. Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

   This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Locations

   2 in total

   Run by

   University of Illinois at Chicago

   See if you can join NCT05344833 on ClinicalTrials.gov

5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Of Illinois Medical Center, Chicago, Illinois

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rush University System for Health, Chicago, Illinois

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

7. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

   The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Endeavor Health - Swedish Hospital, Chicago, Illinois

   Locations

   270 in total

   Run by

   Pfizer

   See if you can join NCT06152575 on ClinicalTrials.gov

8. Mosaic Trial for Stem Cell Transplant Recipients

   The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Northwestern University Feinberg School of Medicine, Chicago, Illinois

   Locations

   3 in total

   Run by

   Northwestern University

   See if you can join NCT06960993 on ClinicalTrials.gov

9. Personalized Autologous Transplant for Multiple Myeloma

   This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them fr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Illinois Chicago, Chicago, Illinois

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT04483206 on ClinicalTrials.gov

10. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Illinois Medical Center at Chicago, Chicago, Illinois

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

11. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

12. Hypofractionation (Radiation) Trial for Multiple Myeloma

    This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT06270888 on ClinicalTrials.gov

13. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Northwestern, Chicago, Illinois

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

14. Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

    Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple my…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05789303 on ClinicalTrials.gov

15. Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

    A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT05192122 on ClinicalTrials.gov